CorMedix Inc. (CRMD)

CorMedix Inc. (CRMD) Healthcare & Pipeline Overview

CorMedix Inc. is a biopharmaceutical company specializing in anti-infective solutions, primarily DefenCath/Neutrolin, targeting catheter-related infections and thrombosis. With a focus on hemodialysis, oncology, and total parenteral nutrition settings, CorMedix operates in the biotechnology sector, addressing a critical need in infection prevention.

What Is the Investment Thesis for CRMD?

CorMedix presents a focused investment opportunity within the biopharmaceutical sector, driven by its lead product candidate, DefenCath/Neutrolin. The company's high gross margin of 88.5% and profit margin of 52.3% indicate strong potential profitability upon successful commercialization. The company's focus on preventing catheter-related infections addresses a critical need in healthcare, particularly among patients undergoing hemodialysis, total parenteral nutrition, and oncology treatments. A key value driver is the potential for DefenCath/Neutrolin to become a standard of care in these settings, reducing healthcare costs associated with catheter-related bloodstream infections. The company's market capitalization of $680.96M, coupled with a P/E ratio of 3.8, suggests potential undervaluation relative to its growth prospects. However, investors should be aware of the risks associated with regulatory approvals and market adoption of new therapies. The company's beta of 1.41 indicates higher volatility compared to the market, reflecting the inherent risks in the biotechnology industry.

Based on FMP financials and quantitative analysis

CRMD Key Highlights

• Market Cap: $0.56B indicates the company's current valuation in the market.
• P/E Ratio: 10.97 suggests the stock is potentially undervalued compared to its earnings.
• Profit Margin: 52.3% demonstrates strong profitability and efficient operations.
• Gross Margin: 88.5% highlights the company's ability to maintain high profitability after accounting for the cost of goods sold.
• FCF: $0.10B shows the company's ability to generate cash after accounting for capital expenditures.

Who Are CRMD's Competitors?

CRMD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CRMD's Key Strengths?

• Proprietary anti-infective solution (DefenCath/Neutrolin)
• High gross and profit margins
• Focus on a specific niche market with unmet medical need
• Experienced management team

What Are CRMD's Weaknesses?

• Reliance on a single product candidate
• Dependence on regulatory approvals
• Limited commercialization experience
• Small size compared to larger pharmaceutical companies

What Could Drive CRMD Stock Higher?

• Potential FDA approval of DefenCath/Neutrolin for catheter-related infections.
• Continued clinical trials to expand the label for DefenCath/Neutrolin to new indications.
• Expansion of commercial infrastructure in preparation for product launch.

What Are the Key Risks for CRMD?

• Regulatory setbacks or delays in the approval process for DefenCath/Neutrolin.
• Competition from established pharmaceutical companies with existing anti-infective products.
• Changes in healthcare reimbursement policies that could impact the pricing and adoption of DefenCath/Neutrolin.
• Reliance on a single product candidate, which exposes the company to significant risk if DefenCath/Neutrolin fails to achieve commercial success.

What Are the Growth Opportunities for CRMD?

• Expansion into New Therapeutic Areas: CorMedix has the opportunity to leverage its expertise in anti-infective solutions to expand into new therapeutic areas beyond catheter-related infections. This could include developing products for the prevention and treatment of other types of hospital-acquired infections, such as pneumonia or surgical site infections. The market for hospital-acquired infection treatments is estimated to reach $25 billion by 2030, presenting a significant growth opportunity for CorMedix. The timeline for this expansion would depend on the company's ability to identify and develop new product candidates, which could take several years.
• Geographic Expansion: CorMedix currently operates in the United States and internationally, but there is significant potential to expand its geographic reach further. This could involve entering new markets in Europe, Asia, and Latin America, where the prevalence of catheter-related infections is high. The global market for anti-infective therapies is expected to grow at a CAGR of 5% over the next five years, driven by increasing healthcare spending and the growing need for effective infection control measures. The timeline for geographic expansion would depend on the company's ability to obtain regulatory approvals in new markets and establish distribution partnerships.
• Strategic Partnerships and Acquisitions: CorMedix could pursue strategic partnerships or acquisitions to accelerate its growth and expand its product portfolio. This could involve partnering with larger pharmaceutical companies to co-develop and commercialize new products, or acquiring smaller biotech firms with complementary technologies. Strategic partnerships could provide CorMedix with access to additional resources and expertise, while acquisitions could add new products to its pipeline and expand its market share. The timeline for these activities is uncertain, as it depends on the availability of suitable partners and acquisition targets.
• Development of New Formulations: CorMedix could develop new formulations of DefenCath/Neutrolin to improve its efficacy and ease of use. This could involve developing a pre-filled syringe formulation that is ready to use, or a sustained-release formulation that provides longer-lasting protection against infection. New formulations could enhance the value proposition of DefenCath/Neutrolin and increase its adoption among healthcare providers. The timeline for developing new formulations would depend on the company's research and development capabilities and the regulatory approval process.
• Direct-to-Patient Marketing: CorMedix could explore direct-to-patient marketing strategies to raise awareness of catheter-related infections and the benefits of DefenCath/Neutrolin. This could involve developing educational materials for patients and their families, or partnering with patient advocacy groups to promote awareness of the issue. Direct-to-patient marketing could help to drive demand for DefenCath/Neutrolin and increase its market share. The timeline for implementing direct-to-patient marketing strategies would depend on the company's marketing budget and the regulatory environment.

What Opportunities Does CRMD Have?

• Expansion into new therapeutic areas
• Geographic expansion into new markets
• Strategic partnerships and acquisitions
• Development of new formulations

What Threats Does CRMD Face?

• Competition from established pharmaceutical companies
• Regulatory setbacks
• Changes in healthcare reimbursement policies
• Product liability claims

What Are CRMD's Competitive Advantages?

• Proprietary anti-infective solution (DefenCath/Neutrolin)
• Focus on a specific niche market (catheter-related infections)
• Potential for regulatory exclusivity
• Established relationships with key healthcare providers

What Does CRMD Do?

CorMedix Inc., established in 2006 and headquartered in Berkeley Heights, New Jersey, is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions for the prevention and treatment of infectious and inflammatory diseases. Originally incorporated as Picton Holding Company, Inc., the company rebranded as CorMedix, Inc. in January 2007, signaling a strategic shift towards its current focus. The company's primary product candidate is DefenCath/Neutrolin, a novel anti-infective solution designed to reduce and prevent catheter-related infections and thrombosis in patients requiring central venous catheters. These catheters are commonly used in clinical settings such as hemodialysis, total parenteral nutrition, and oncology, where patients are particularly vulnerable to bloodstream infections. CorMedix aims to address the significant unmet medical need in these areas by providing a prophylactic solution that minimizes the risk of infection and improves patient outcomes. With a team of 64 employees, CorMedix operates both in the United States and internationally, seeking to expand the reach of its innovative therapies and establish itself as a key player in the anti-infective market.

What Products and Services Does CRMD Offer?

• Develops and commercializes therapeutic products.
• Focuses on prevention and treatment of infectious diseases.
• Addresses inflammatory diseases.
• Offers anti-infective solutions for catheter-related infections.
• Targets thrombosis in patients requiring central venous catheters.
• Provides solutions for hemodialysis patients.
• Offers solutions for patients requiring total parenteral nutrition.
• Serves oncology patients.

How Does CRMD Make Money?

• Develops proprietary anti-infective solutions.
• Seeks regulatory approval for its products.
• Commercializes approved products through sales and marketing efforts.
• Generates revenue through product sales to healthcare providers and institutions.

What Industry Does CRMD Operate In?

CorMedix operates within the biotechnology industry, a segment of the healthcare sector characterized by rapid innovation and high regulatory hurdles. The market for anti-infective therapies is driven by the increasing prevalence of hospital-acquired infections and the growing need for effective prevention strategies. The competitive landscape includes established pharmaceutical companies and smaller biotech firms developing novel antimicrobial agents. CorMedix's focus on catheter-related infections positions it within a niche market with significant growth potential, as these infections represent a major cause of morbidity and mortality in healthcare settings. The company's success depends on its ability to navigate the regulatory approval process and effectively commercialize its lead product candidate, DefenCath/Neutrolin.

Who Are CRMD's Key Customers?

• Hospitals and medical centers
• Hemodialysis centers
• Oncology clinics
• Healthcare providers administering total parenteral nutrition

Company Profile

CorMedix Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Berkeley Heights, US. The company is led by CEO Joseph Todisco. CRMD has traded publicly since 2010.

CorMedix Inc. Financial Trajectory

CorMedix Inc. (CRMD) reported $127.4M in revenue for Q1 2026, a decline of 0.9% compared to the prior quarter. The company recorded net income of $38.6M, with diluted EPS of $0.42. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, CRMD averaged $0.53 in diluted EPS.

How CorMedix Inc. Is Valued

CorMedix Inc. carries a market capitalization of $680.96M, placing it in the small-cap category. Relative to its peer group, CRMD's quantitative score of 95/100 is above the peer average of 78/100.

ROE 50%Key Financial Metrics

Return on equity for CorMedix Inc. stands at 50.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 22.2%, showing how much profit it generates from its asset base. CRMD trades at a trailing price-to-earnings ratio of 3.80, below the Healthcare sector average of ~23x. Its free cash flow yield is 28.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.98 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 26.3%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 4/9Financial Health

CorMedix Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.48 places it in the grey zone, a middle ground that warrants monitoring.

FY2026 estForward Outlook

Wall Street analysts project CorMedix Inc. revenue of about $334.1M for fiscal 2026, with EPS near $0.50. The estimate reflects 3 contributing analysts.

Net buyingInsider Activity

Over the past six months, CorMedix Inc. insiders filed 25 SEC Form 4 transactions — 10 sales and 15 purchases. On net that is roughly 684K shares acquired (about $800K) — insiders putting money in tends to read as conviction.

CRMD Financials

CRMD Latest News

CRMD Analyst Consensus

CRMD MoonshotScore

Latest CorMedix Inc. Analysis

CRMD Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources